[Skip to Content]
[Skip to Content Landing]
July 20, 1994

Test for Lyme Disease in a Prepaid Health Plan-Reply

JAMA. 1994;272(3):203. doi:10.1001/jama.1994.03520030043024

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.  —We thank Mr Berardi and Dr Seder for their comments concerning our article on the use of Lyme disease serologic tests. Needless to say, we agree that a more specific and sensitive serologic test will yield results that are more useful to clinicians attempting to confirm or refute the diagnosis of Lyme disease, particularly in a patient with signs and symptoms compatible with either early-stage or late-stage Lyme disease. In fact, laboratory testing for Lyme disease at the facility we studied was subsequently changed to a whole-cell sonicate enzyme immunoassay, followed by Western blot testing of all positive specimens. In addition, we are currently involved in a collaborative study with the Centers for Disease Control and Prevention that is comparing these results with an experimental new ELISA test.However, the purpose of our study was to examine the appropriateness and utility of Lyme disease serologic testing as currently

First Page Preview View Large
First page PDF preview
First page PDF preview